EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

в текстеNormalized hemostasis as a new goal in the treatment of hemophilia A in children: the role of efanesoctocog alfa

Pavel A. Zharkov

Pediatric Hematology/Oncology and Immunopathology · 30.06.2026 · 25 (2) · 191-198

DOI: 10.24287/j.1130 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pediatric Hematology/Oncology and Immunopathology, online erschienen am 30.06.2026. Verfasst von Pavel A. Zharkov. Die Arbeit nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Hemophilia A remains one of the major challenges in pediatric hematology, because it is during childhood that long-term disease outcomes develop, including the degree of joint damage, the level of physical activity, social adaptation, and quality of life in adulthood. Over the past decades, hemophilia A management has undergone a remarkable transformation, from treating individual bleeding episodes to early prophylaxis, with the aim of preserving joint health and achieving the so-called normalized hemostasis. This review summarizes current knowledge on hemophilic arthropathy, the evolution of the goals of prophylaxis, and the clinical and pharmacokinetic characteristics of efanesoctocog alfa, an ultra-long-acting factor VIII that functions independently of endogenous von Willebrand factor. Special attention is given to pivotal results from the phase III XTEND-Kids and XTEND-1 studies, indirect comparative analyses of standard and extended-half-life products, and non-factor therapy with emicizumab.

Zitieren

APA

Zharkov, P. A. (2026). в текстеNormalized hemostasis as a new goal in the treatment of hemophilia A in children: the role of efanesoctocog alfa. Pediatric Hematology/Oncology and Immunopathology, 25(2), 191-198. https://doi.org/10.24287/j.1130

Vancouver

Zharkov PA. в текстеNormalized hemostasis as a new goal in the treatment of hemophilia A in children: the role of efanesoctocog alfa. Pediatric Hematology/Oncology and Immunopathology. 2026;25(2):191-198. doi:10.24287/j.1130

BibTeX
@article{Zharkov2026,
  author = {Zharkov, Pavel A.},
  title = {в текстеNormalized hemostasis as a new goal in the treatment of hemophilia A in children: the role of efanesoctocog alfa},
  journal = {Pediatric Hematology/Oncology and Immunopathology},
  year = {2026},
  volume = {25},
  number = {2},
  pages = {191--198},
  doi = {10.24287/j.1130}
}
Kostenlos starten →